Bionic nano-drug delivery system based on PD1 engineered cancer cell membrane and construction method of bionic nano-drug delivery system

Through a bionic nanodrug delivery system based on PD1-engineered cancer cell membrane, the adaptability and drug resistance problems in targeted hepatocellular carcinoma are solved, efficient and stable drug delivery and immune escape intervention are achieved, and the therapeutic effect is improved and biosecurity.

CN119055612AActive Publication Date: 2024-12-03WEST CHINA HOSPITAL SICHUAN UNIV

Patent Information

Application Number
CN202411236887.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-12-03
Estimated Expiration
2044-09-04

AI Technical Summary

Technical Problem

The existing targeted hepatocellular carcinoma drugs have problems such as poor adaptability, high drug resistance and low cure rate. The nanodrug delivery system has great stability and toxic side effects in the organism, which limits its application scope.

Method used

Using a bionic nanodrug delivery system based on PD1-engineered cancer cell membrane, a combination of PLGA drug-loaded core and PD1-CCNPs is used to achieve efficient tumor active targeting and immune escape intervention, avoiding negative effects on T cells and normal cells.

Benefits of technology

It realizes efficient, stable and long-term circulating delivery of nanodrugs, significantly downregulates MYC and PD-L1 in liver cancer cells, affects tumor immune escape, and improves therapeutic effect and biosafety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055612A_ABST
    Figure CN119055612A_ABST
Patent Text Reader

Abstract

The invention relates to a construction method of a bionic nano-drug delivery system based on a PD1 engineered cancer cell membrane, which comprises the following steps: using PLGA (poly (lactic-co-glycolic acid)) to prepare a nano-particle core from a Pin1 inhibitor, and assisting with fluorescence labeling; pD1 is subjected to engineering expression in cancer cells, cell membranes rich in PD1 are extracted, API-1-NPs are wrapped and modified with PD1 engineering cancer cell membranes, the composite nanoparticles API-1 (at) PD1-CCNPs are obtained, it can be guaranteed that stable and long-acting circulation is kept in the delivery process, the process that a carrier is rapidly and effectively delivered to tumor cells and organs in a targeted mode can be tracked in real time in vivo, and the targeted delivery effect of the carrier to the tumor cells and organs is achieved. Once internalized by cancer cells, the drug API-1 wrapped by the drug can be effectively released and play a role, and the function of Pin1 is inhibited; the composite nanoparticles API-1 (at) PD1-CCNPs can effectively lower the protein level of MYC and PD-L1 in liver cancer cells, so that a tumor immune microenvironment is effectively and synergistically reprogrammed, and tumor immune escape is influenced.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention belongs to the field of biotechnology, and in particular relates to a bionic nano drug delivery system based on PD1 engineered cancer cell membrane and a construction method thereof. Background Art

[0002] At present, there are very limited systemic therapeutic drugs for hepatocellular carcinoma - molecular targeted drugs and immune drugs. Since the FDA approved sorafenib for the treatment of advanced liver cancer in 2007, drugs that have been approved for liver cancer indications include: sorafenib and lenvatinib for first-line treatment; regorafenib, ramucirumab, cabozantinib, apatinib, pembrolizumab, nivolumab, and carrelizumab for second-line treatment. In addition to monoclonal antibody immune drugs, other targeted drugs are small molecule multi-target oral tyrosine kinase inhibitors (tyrosine kinase inhibitor, TKI), which have anti-angiogenesis and tumor cell proliferation inhibition effects. TKIs approved for liver cancer indications in China include sorafenib, lenvatinib, regorafenib, and apatinib; the only immune checkpoint inhibitor is carrelizumab. Although sorafenib is used as a first-line drug for the treatment of liver cancer, its objective response rate is only 2%, and monoclonal antibody immunotherapy is only effective for some patients. In recent years, targeted combined immunotherapy for hepatocellular carcinoma has made substantial progress, but also faces new challenges. Exploring promising therapeutic targets, therapeutic drugs and treatment methods for liver cancer is an urgent need for patients and is in line with the development trend of scientific research centered on human health.

[0003] Molecular targeted drugs use the molecular biological differences between tumor cells and normal cells (including different characteristics such as genes, enzymes, and signal transduction) to inhibit the growth and proliferation of tumor cells and finally kill them. The following problems still exist: ① Compatibility. If the targeted drug does not match the patient's genes, it will cause great harm to the patient. Experiments have shown that if targeted drugs are taken blindly without genetic testing, it is possible to die faster, and if it is stopped when it is really ineffective, it will delay the best time for treatment. ② Success rate and cure rate. Current targeted therapies do not have a radical effect, and are not effective for all tumors and all patients. For example, the targeted drugs Iressa and Tarceva for the treatment of locally advanced and metastatic non-small cell lung cancer are now reported in the literature to have an efficacy of only about 40%, and the tumor control rate is only about 70%. Sorafenib for the treatment of renal cancer and liver cancer, and Gleevec for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors, have also failed to achieve a radical effect. ③ Drug resistance. Many patients who use targeted drugs in the clinic find that the drugs are ineffective after taking them for a period of time. This is because various specific molecular targeted drugs act on a certain protein or molecule of a certain cancer cell and can only inhibit one pathway of tumor growth. When one pathway is inhibited, tumor cells will continue to seek their own "way out" and choose other pathways to synthesize the substances they need for their own growth. Over time, the molecular targeted drugs will lose their effectiveness.

[0004] With the rapid development of nanotechnology, nano drug delivery technology with broad application prospects has emerged and has become a popular emerging technology in drug formulation technology in recent years. The types of nano drug carriers are quite extensive. According to the properties of nano materials, they can be divided into inorganic nano carriers, such as mesoporous silica nano materials, carbon nano materials, etc.; organic nano carriers, such as liposomes, polylactic acid, chitosan, dendrimers, etc. and metal nano carriers, such as gold nanoparticles, silver nanoparticles, etc. Compared with traditional drugs and systemic therapeutic drugs, nano delivery systems show many advantages: ① Nano drug carriers can increase the solubility of drugs and improve drug stability, thereby reducing drug dosage and improving drug efficacy; ② Nano drug carriers can achieve precise treatment through active / passive targeting; ③ Reduce the obstruction of physiological barriers to drugs and increase the blood circulation time of drugs in the body; ④ Nano drug carriers provide an opportunity for the development of stimulus-responsive intelligent nano drug delivery systems; ⑤ Nano drug carriers can achieve multifunctionality and integrated diagnosis and treatment.

[0005] Existing studies have shown that organic drug carriers are liposomes, polymer micelle particles formed by some organic molecules through the self-assembly process, or designed dendritic molecules and polymer particles. The design principle of these organic carriers is simple, and they can achieve controlled release of loaded drugs through their own deformation or degradation. Organic nano drug delivery systems provide many advanced possibilities for targeted drug delivery and release, but they still face a series of limitations and challenges, which are reflected in the following shortcomings: ① organic nanoparticles have poor stability in the body and are easily cleared by the reticuloendothelial system; ② the toxic side effects of their own organic molecular components are large; ③ the molecular weight and size of the organism are difficult to control; ④ the drug release kinetics are unstable, which greatly limits its application range. Summary of the invention

[0006] In order to solve the above problems, the present invention provides a bionic nano drug delivery system based on PD1 engineered cancer cell membrane and a construction method thereof. The bionic nano drug delivery system of the present invention has the following advantages: (1) The organic nano drug delivery system packaged by the cell membrane has a simple preparation method and components, is non-toxic, has a bionic surface that is closer to reality, and has extremely high biocompatibility; (2) It can present antigens of the same type of cancer cells to immune cells, and also has good immune escape and homotypic binding ability, and can effectively carry and release drugs in animal models; (3) PD1 is engineered to express in cancer cells, PD1-rich cell membranes are extracted, PD1-CCNPs nanoparticles are synthesized, and CCNPs are given efficient tumor active targeting based on PD1 / PD-L1 binding affinity, which can more efficiently and accurately carry drugs to solid tumors; (4) PD1 on CCNPs may competitively bind to PD-L1 on tumor cells, interfere with the inhibition of immune T cell function by PD-L1 on the surface of tumor cells, and further affect tumor immune escape. This strategy avoids the negative effects of PD1 / PD-L1 inhibitors on T cells and normal cells in treating tumors.

[0007] The technical solution of the present invention is:

[0008] A method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane comprises the following steps:

[0009] (1) Preparation of API-1-NPs drug-loaded cores;

[0010] PLGA and API-1 are dissolved in acetone to obtain an organic phase; under stirring conditions, the organic phase is quickly added into water, and after stirring for reaction, an API-1-NPs drug-loaded core is obtained;

[0011] (2) Construction of API-1@PD1-CCNPs:

[0012] First, a PD1 overexpression cell line was established, and then the cell membrane was extracted; the extracted cell membrane was wrapped on the surface of API-1-NPs to obtain composite nanoparticles API-1@PD1-CCNPs.

[0013] In step (1), a certain proportion of carbon-based dendritic macromolecular structure G0-C14 and surfactant TPGS are added to the organic phase. This can effectively increase the pore structure of the nanoparticles and improve the drug encapsulation efficiency and stability; the amount of G0-C14 added is 0.025-0.125 mg / mL, and the mass ratio of the surfactant TPGS to PLGA is 1:5-1:10;

[0014] In step (1), a dye is also added to construct fluorescent nanoparticles; the amount of the fluorescent dye added is 1% of the mass of PLGA.

[0015] The fluorescent nanoparticles are DiD and / or DiO. By using dyes such as DiD (ex / em=644 / 663nm) and DiO (ex / em=484 / 501nm), they are added during the synthesis of nanoparticles to synthesize fluorescent nanoparticles, which are collected by centrifugation, thereby facilitating the study of the uptake and transport of nanoparticles in cells.

[0016] In step (2), the specific operation of establishing a PD1 overexpressing cell line is as follows:

[0017] First, construct a PD1 target gene overexpression vector, then perform transfection or infection, select drugs for screening based on the screening gene of the expression vector, and expand and culture the screened monoclonal cells and identify them.

[0018] The sequence of the target gene is shown in SEQ ID No. 1;

[0019] The drug is puromycin or G418.

[0020] In step (2), the specific operation of extracting the cell membrane is:

[0021] Start to expand the cells in large quantities 5-7 days before extracting the cell membrane, digest the cells with PBS, collect and wash them three times by centrifugation with PBS, resuspend the last collected cells in hypotonic buffer, then sonicate in ice water, collect the supernatant after centrifugation, and repeat the above "resuspending-sonication-centrifugation" operation for the precipitate, mix the two supernatants and centrifuge, take the supernatant and centrifuge it, add Tris-HCl to the obtained precipitate, blow and centrifuge, and the precipitate is the purified cell membrane.

[0022] The specific composition of the hypotonic buffer is:

[0023] 20 mM Tris-HCl, 10 mM KCl, 2 mM MgCl2, 200 mM protease inhibitor concentrate (20 μmol, i.e., 100× protease inhibitor concentrate);

[0024] The PBS is a PBS solution containing 2 mM EDTA, and the Tris-HCl is a Tris-HCl solution containing 1 mM EDTA.

[0025] The specific operation of encapsulating the extracted cell membrane on the surface of API-1-NPs is as follows:

[0026] The extracted cell membrane was added to the syringe of the squeezer, prepared with 1×PBS to a total volume of 1 mL, and squeezed back and forth with the squeezer for more than 20 times, and then the empty membrane bubble structure of the cell membrane was collected from another syringe; the empty membrane bubble and API-1-NPs were mixed according to a proportion and added to the syringe of the squeezer, and squeezed back and forth with the squeezer for more than 20 times, and then the squeezed membrane-wrapped material was collected from another syringe, ultrafiltered and centrifuged, and concentrated and collected.

[0027] The method constructs a bionic nano drug delivery system based on PD1 engineered cancer cell membrane.

[0028] The beneficial effects of the present invention are:

[0029] (1) The present invention provides a method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane, wherein the nanoparticle core (API-1-NPs) made of Pin1 inhibitor (a small molecule targeted anticancer drug) is made by using PLGA (an FDA-certified organic polymer material) and assisted by fluorescent labeling; PD1 is engineered to express in cancer cells, PD1-rich cell membranes are extracted, and the API-1-NPs are modified by wrapping the PD1 engineered cancer cell membrane to obtain composite nanoparticles API-1@PD1-CCNPs, which can not only ensure stable and long-lasting circulation during the delivery process, but also track the process of rapid and effective targeted delivery of the carrier to tumor cells and organs in real time in vivo. Once internalized by cancer cells, the encapsulated drug (API-1) can be effectively released and exert its effect to inhibit Pin1 function; the composite nanoparticles API-1@PD1-CCNPs can effectively downregulate the protein levels of MYC and PD-L1 in liver cancer cells, thereby effectively and synergistically reprogramming the tumor immune microenvironment and affecting tumor immune escape.

[0030] (2) The API-1-NPs drug-loaded core of the present invention is a uniformly dispersed nanoparticle structure, which has the characteristics of high targeting, high delivery efficiency and high biocompatibility compared with ordinary nanoparticles; the composite nanoparticles API-1@PD1-CCNPs have good stability and significant efficacy, and have stronger water solubility and high biosafety factor than naked drug molecules; the API-1@PD1-CCNPs of the present invention are easy to store, and the preparation process is simple and can be completed at room temperature without relying on precision temperature control equipment, which greatly reduces the complexity of operation; the present invention combines the characteristics and advantages of organic nanomaterials, biomaterials and fluorescent signals, and can achieve rapid, high sensitivity and high specificity in vivo delivery and visual analysis of anti-tumor small molecule drugs; the present invention has no special requirements for the encapsulated small molecule drugs, has a wide range of applications, and can appropriately replace the targeted drug molecules according to different treatment needs. It has universality and can be applied to other tumor models.

[0031] (3) The PD1-CCNPs carrier of the present invention can effectively induce anti-tumor immune response in vivo. Cancer cell membrane provides a more realistic bionic surface for nanoparticles. Through bionic surface functionalization, immune escape and homologous targeting behavior will significantly enhance their ability to target and retain tumors. At the same time, tumor antigens alone are not enough to counteract the immunosuppressive effects of the tumor microenvironment. Combined with the immune regulatory molecular mechanism (PD1 / PD-L1 immune checkpoint), while strengthening active targeting and giving full play to the advantages of nano-drug delivery technology, it can more efficiently induce anti-cancer immune response. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0033] Figure 1 Shown is a schematic diagram of the anti-liver cancer strategy based on active targeting of immune checkpoints using a biomimetic nano-drug delivery system in conjunction with Pin1 inhibitors;

[0034] Figure 2 Displayed as a material characterization diagram; where Figure 2 a is a schematic diagram of the synthesis of the API-1@PD1-CCNPs material; Figure 2 b is the detection of DNA, mRNA and protein levels by PCR, qRT-PCR, WB, immunofluorescence flow cytometry and other methods; Figure 2 c is a transmission electron microscopy image of the API-1@PD1-CCNPs material; Figure 2 d-2f show the apparent hydrodynamic size and Zeta potential of the nanoparticles measured using a Zetasizer, where, Figure 2 d shows the particle size of API-1@PD1-CCNPs, which is a uniform particle size of about 100 nm. Figure 2 e shows the Zeta potential, which is about -20mV. Figure 2 f shows the change in particle size over 3 weeks, which is almost stable at around 100 nm. This result indicates that the physical properties of the synthesized nanoparticles are stable.

[0035] Figure 3 Shown is the growth inhibition and molecular regulation of SK-Hep1 by API-1@PD1-CCNPs; Figure 3 a is the effect of API-1, API-1-NPs, and API-1@PD1-CCNPs on the proliferation of liver cancer cells. Figure 3b, 3c respectively verified whether API-1@PD1-CCNPs had an effect on the nuclear transport and export of tumor suppressor miRNAs by immunofluorescence staining IF and qRT-PCR methods;

[0036] Figure 4 It shows that API-1@PD1-CCNPs can effectively target and intervene in CDX subcutaneous tumor model; Figure 4 a: Establishment of CDX subcutaneous tumor model; Figure 4 b-4d is the detection of targeted delivery efficiency; Figure 4 e is the detection of tumor inhibition effect; Figure 4 f is immunohistochemical analysis;

[0037] Figure 5 The tumor suppressive effect and CD8 induction of API-1@PD1-CCNPs in spontaneous hepatocellular carcinoma model mice were shown. + T cell infiltration. Figure 5 a is to verify tumor targeting and calculate drug delivery efficiency; Figure 5 b is the detection of tumor treatment effect of API-1@PD1-CCNPs; Figure 5 c is the percentage, number and spatial distribution of various immune cell infiltrations in the tumor microenvironment after API-1@PD1-CCNPs treatment. DETAILED DESCRIPTION

[0038] To make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described in detail below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other implementation methods obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.

[0039] The above technical solution is described in detail below in conjunction with specific embodiments.

[0040] Example 1

[0041] This embodiment provides a method for constructing a bionic nano drug delivery system based on PD1 engineered liver cancer cell membranes. Figure 1 As shown, the following steps are included:

[0042] (1) Preparation of API-1-NPs drug-loaded cores;

[0043] 10 mg PLGA and 1 mg API-1 are dissolved in acetone, and the organic phase solution is placed at 37°C and subjected to constant temperature ultrasound until dissolved, and then a certain proportion of carbon-based dendritic macromolecular structure G0-C14 and surfactant TPGS are added to the organic phase formula; the amount of G0-C14 added is 0.025-0.125 mg / mL, and the mass ratio of the surfactant TPGS to PLGA is 1:5-1:10; preferably, in this embodiment, the amount of G0-C14 added is 0.075 mg / mL, and the mass ratio of the surfactant TPGS to PLGA is 1:7.5;

[0044] 1 mL was quickly added to 5 mL sterile water at a speed of 1200 rpm / min, DiD (ex / em=644 / 663 nm) was added as a fluorescent dye, and stirred for 30 min to construct fluorescent nanoparticles API-1-NPs stably dispersed in the solution. The solution was placed in a rotary evaporator to quickly evaporate the organic solvent and evaporate about 90% of the water for concentration; the amount of the fluorescent dye DiD added was 1% of the mass of PLGA;

[0045] (2) Construction of API-1@PD1-CCNPs:

[0046] First, a PD1 overexpression cell line was established, and then the cell membrane was extracted; the extracted cell membrane was wrapped on the surface of API-1-NPs to obtain composite nanoparticles API-1@PD1-CCNPs;

[0047] Establishment of PD1 overexpression cell line: construct an overexpression vector of PD1 target gene (as shown in SEQ ID No. 1), and use virus infection; select drugs for screening according to the screening gene of the expression vector. The expression vector selected in this example is a plasmid with an ampicillin resistance gene, and the selected drug is puromycin; the selected monoclonal cells are expanded and cultured; the WB method is used to detect the engineered expression of PD1 at the protein level ( Figure 2 b).

[0048] The PD1 target gene is shown in SEQ ID No. 1, and the specific sequence is as follows:

[0049] ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTAC

[0050] AACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTG

[0051] GAACCCCCCCACCTTCTCCCCAGCCCTGCTCGGTGGTGACCGAAGGGGAC

[0052] AACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCT

[0053] AAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCC

[0054] TTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCA

[0055] CACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCG

[0056] GCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCA

[0057] AGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGA

[0058] GAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGC

[0059] CGGCCAGTTCCAAACCCTGGTGGTTGGTGTCGTGGGCGGCCTGCTGGGC

[0060] AGCCTGGTGCTGCTAGTCTGGGTCCTGGCCGTCATCTGCTCCCGGGCCGC

[0061] ACGAGGGACAATAGGAGCCAGGCGCACCGGCCAGCCCCTGAAGGAGGA

[0062] CCCCTCAGCCGTGCCTGTGTTCTCTGTGGACTATGGGGAGCTGGATTTCC

[0063] AGTGGCGAGAGAAGACCCCGGAGCCCCCCGTGCCCTGTGTCCCTGAGCA

[0064] GACGGAGTATGCCACCATTGTCTTTCCTAGCGGAATGGGCACCTCATCCC

[0065] CCGCCCGCAGGGGCTCAGCTGACGGCCCTCGGAGTGCCCAGCCACTGAG

[0066] GCCTGAGGATGGACACTGCTCTTGGCCCCTCTGA;

[0067] Cell membrane extraction: a) Start to amplify cells a few days before extracting cell membranes, and ensure that they can grow to about 100 million (using diameter Each dish has about 10 7 cells); b) prepare hypotonic buffer: 20 mM Tris-HCl, 10 mM KCl, 2 mM MgCl2, 1 protease inhibitor (pre-prepared protease inhibitor concentrate can be used), total volume 10 mL, pH 7.5; c) use 2 mM Digest the cells with 1×PBS containing EDTA, collect them into EP tubes, and wash them three times with 1×PBS by centrifugation (1000×g, 8min); d) resuspend the last collected cells with hypotonic buffer; e) ultrasonicate them in ice water with an ultrasonic water bath (power 50W, frequency 40kHz) for 5-10min (this step can be changed to grinding with a glass cell grinder), collect the liquid, and centrifuge at 3200×g for 5min; f) take the supernatant, repeat steps 4 and 5 with the precipitate, and take the supernatant together; g) mix the two supernatants, centrifuge at 20000×g, 20min, 4℃; h) take the supernatant, centrifuge at 10000×g, 4℃ for 1h; i) remove the supernatant, add 10mM Tris-HCl (pH 7.5, containing 1mM EDTA) to the precipitate, blow, centrifuge at 10000×g, 4℃ for 1h, and the precipitate is the purified cell membrane. j) remove the supernatant, and resuspend the precipitate (cell membrane) with PBS buffer as needed.

[0068] Cell membrane wrapping: Add the extracted cell membrane into the syringe of the squeezer, prepare it with 1×PBS to a total volume of 1 mL, squeeze it back and forth with the squeezer for more than 20 times, and then collect the squeezed empty membrane bubble structure from another syringe; Mix the empty membrane bubble (or collected cell membrane) and API-1-NPs in proportion and add them to the syringe of the squeezer. Squeeze it back and forth with the squeezer for more than 20 times, and then collect the squeezed membrane wrapping material from another syringe, perform ultrafiltration centrifugation, and concentrate the collection.

[0069] Experimental Example 1

[0070] Transmission electron microscopy, dynamic light scattering particle size analyzer, fluorescence spectrophotometer, HPLC, microplate reader, etc. were used to characterize and analyze the physical properties of API-1@PD1-CCNPs and synthetic intermediates, including particle size, potential, drug encapsulation efficiency and release rate.

[0071] Particle size and potential: Under a transmission electron microscope, the solution containing API-1@PD1-CCNPs was diluted and dropped onto a copper grid, the excess solvent was evaporated, and its morphology was detected using a transmission electron microscope ( Figure 2 c). API-1@PD1-CCNPs were diluted with ultrapure water or cell culture medium, and the apparent hydrodynamic size and Zeta potential of the nanoparticles were measured using a Zetasizer ( Figure 2 d, e, f). Fluorescence spectra were obtained by Edinburgh FS920 fluorescence spectrometer.

[0072] Encapsulation efficiency: Take 1 mL of API-1@PD1-CCNPs, centrifuge at 15000 r / min for 10 min, aspirate the supernatant solution, and dilute to an appropriate mass concentration. Use an ELISA reader and HPLC to measure the content of API-1 according to spectral conditions. Calculate the drug loading rate and encapsulation efficiency based on the total mass of the carrier and the total amount of drug administered.

[0073] Release rate: Take 2mL of API-1@PD1-CCNPs and PD1-CCNPs, add them into dialysis bags (MWCO: 7000Da), immerse them in 18mL of buffer (0.1% Tween 80, PBS, pH 7.4) and buffer (0.1% Tween 80, PBS, pH 5.5), respectively, and shake them in a shaker at 100r / min at 37℃ in the dark; take out 1mL to detect its absorbance and add 1mL of corresponding fresh buffer at 0.5, 1, 2, 4, 8, 12, 24, 36 and 48h, respectively, measure their ultraviolet absorption at the maximum absorption wavelength of 278nm, and calculate the drug release rate.

[0074] Experimental Example 2

[0075] The biocompatibility of the PD1-CCNPs drug delivery system was verified at the cellular level.

[0076] Select a variety of liver cancer cell lines (SK-Hep1, HepG2, Huh7, etc.), treat with different concentrations of homologous PD1-CCNPs, and use MTT assay, clone formation and Ki67 immunofluorescence assay to detect its cytotoxicity to liver cancer cells. Select untreated liver cancer cells as the control group. The maximum carrier concentration is determined based on the experimental results.

[0077] MTT activity and clone formation: Select liver cancer cell line (SK-Hep1 as an example), digest with trypsin, resuspend the cells in DMEM complete medium, and add 100 μL cell suspension for a total of 3×10 3Cells were seeded in 96-well plates, and different concentrations of cell membrane homologous PD1-CCNPs were added. A concentration gradient group was set, and 5 replicate wells were designed for each time point. 20 μL MTT was added to each well every other day. After incubation at 37°C for 4 hours, the culture medium was discarded, and the cells were resuspended in 100 μL DMSO. The absorbance was measured at a wavelength of 540 nm on an ELISA reader, and the cell growth curve was finally drawn. At the same time, 1×10 4 SK-Hep1 cells were evenly planted in a 6-well plate, PD1-CCNPs were added to the culture medium, and a concentration gradient group was set. After 5 days, the culture was terminated and stained with 0.5% crystal violet at room temperature for 20 minutes. Then, the outside of the well plate was gently rinsed with running water to make it fully faded, and the well plate was dried. Finally, the photo was taken and the clones were counted. The untreated cell line was used as the control group to detect the proliferation ability ( Figure 3 a).

[0078] Immunofluorescence: 1. Plate laying: Use tweezers to add sterilized glass slides (or use confocal glass-bottom dishes) into a 24-well plate, and lay liver cancer cells at a density of 80,000 / well overnight; 2. Add drugs: Add different concentrations of drugs (PD1-CCNPs) for different treatment times according to experimental requirements; 3. Staining: Wash with 1×PBS, 4×5min; Fix with 4% paraformaldehyde at room temperature for 30min, add 500μL to each well; Wash with 1×PBS, 4×5min; Transmembrane: Contains 0.25% Triton and 0.2% Tween 500 μL of the mixture was added to each well and incubated for 15 min; washed with 1× PBS for 4×5 min; blocked primary antibody: diluted primary antibody (6% BSA configuration) at a ratio of 1:200, incubated at room temperature for 2 h; washed with 1× PBS for 4×5 min; added secondary antibody: diluted fluorescent secondary antibody (6% BSA configuration) at a ratio of 1:200, incubated at room temperature for 1 h; washed with 1× PBS for 4×5 min; patch: took out the glass slide, pasted it face down on the glue-dropped carrier, dried overnight at room temperature, and observed and photographed under a laser confocal microscope.

[0079] Experimental Example 3

[0080] Effect of API-1@PD1-CCNPs on the tumor biological characteristics of liver cancer cells.

[0081] (1) Effect of API-1@PD1-CCNPs on the proliferation of liver cancer cells

[0082] Liver cancer cell lines (SK-Hep1, HepG2, Huh7, etc.) were selected and treated with API-1, API-1-NPs, and API-1@PD1-CCNPs, respectively. The effects on the proliferation of liver cancer cells were detected using MTT assay, clone formation assay, and Ki67 immunofluorescence assay. Untreated and PD1-CCNPs-treated liver cancer cells were selected as the control group. The optimal drug concentration and duration of drug effect for each liver cancer cell line were determined based on the experimental results.

[0083] MTT activity and clone formation: Different concentrations of drugs (API-1, API-1-NPs, API-1@PD1-CCNPs) were added according to the experimental requirements and treated for different time periods ( Figure 3 a). The specific experimental operation was carried out according to the above scheme.

[0084] Ki67 immunofluorescence: Different concentrations of drugs (API-1, API-1-NPs, API-1@PD1-CCNPs) were added according to the experimental requirements and treated for different time periods. The specific experimental operation was performed according to the above protocol.

[0085] (2) Effects of API-1@PD1-CCNPs on the invasion and migration of liver cancer cells

[0086] Liver cancer cell lines (SK-Hep1, HepG2, Huh7, etc.) were selected and treated with API-1, API-1-NPs, and API-1@PD1-CCNPs, respectively. Transwell assay, invasion assay, and wound healing assay were used to detect their effects on invasion and migration abilities.

[0087] Migration and invasion of the transwell chamber: Untreated and PD1-CCNPs-treated liver cancer cells were selected as the control group. Taking SK-Hep1 as an example, after being treated with API-1, API-1-NPs, and API-1@PD1-CCNPs for 48 hours, the cells were trypsinized and resuspended in serum-free DMEM. 700 μL of DMEM complete medium was added to each well of the 24-well plate, and 150 μL of cell suspension was gently added to the Transwell chamber with and without matrix gel on the bottom surface, so that the bottom of the chamber was fully in contact with the lower liquid surface. After 48 hours of culture in a 37°C cell incubator, the cells were taken out and fixed with 4% paraformaldehyde solution at room temperature for 20 minutes, and then the chamber was placed in 0.5% crystal violet and stained at room temperature for 20 minutes, and then the inside and outside of the chamber were gently rinsed with running water to make it fully faded, and then the inner and outer walls of the chamber were carefully wiped with a cotton swab, and the chamber was dried. Finally, the chamber was placed under a slide, placed under an upright microscope, and 5 fields of view were randomly selected under a 400× field of view, and the cells were photographed and counted.

[0088] Scratch healing: We plated 5 × 10 6 SK-Hep1 cells treated in the above experiment were plated for 24 hours. The cell surface was lightly scratched with a gun tip and the medium was replaced with serum-free medium. Five fields of view were randomly selected and the width of the scratch at the same position was observed and recorded under a microscope every 12 hours. The migration ability of SK-Hep1 was statistically analyzed. The migration and invasion abilities of SK-Hep1 treated with API-1, API-1-NPs, and API-1@PD1-CCNPs were compared with those of SK-Hep1 in the control group.

[0089] (3) Effect of API-1@PD1-CCNPs on tumor angiogenesis

[0090] Hepatocellular carcinoma cell lines (SK-Hep1, HepG2, Huh7, etc.) were selected and treated with API-1, API-1-NPs, and API-1@PD1-CCNPs. The culture medium was collected by centrifugation and the effect on angiogenesis ability was observed using the umbilical vein epithelial cell (HUVEC) tube formation experiment.

[0091] HUVEC tube formation: The cell culture medium of each group that had been cultured for 3 days was collected, and the mixed umbilical vein epithelial cells (HUVEC) were inoculated in a 96-well plate pre-coated with matrix gel. Five random fields of view were photographed every 2 hours and the microtubule structures were calculated. Finally, the number of tubes in each group was counted. Similarly, untreated and PD1-CCNPs-treated liver cancer cells were selected as the control group.

[0092] (4) Can API-1@PD1-CCNPs induce apoptosis / autophagy of tumor cells?

[0093] Hepatoma cell lines (SK-Hep1, HepG2, Huh7, etc.) were selected and treated with API-1, API-1-NPs, and API-1@PD1-CCNPs. Flow cytometry, immunofluorescence assay, WB, etc. were used to detect whether the hepatoma cells had apoptosis or autophagy. Untreated and PD1-CCNPs-treated hepatoma cells were selected as the control group.

[0094] Flow cytometric detection of apoptosis: After liver cancer cells were treated with the corresponding drugs API-1, API-1-NPs, and API-1@PD1-CCNPs, adherent cells were digested and collected with 0.25% trypsin, centrifuged at room temperature for 5 minutes at 1500rpm, and 300μL of 1×Binding Buffer was added to suspend the cells. After adding 5μL of AnnexinV-FITC and mixing, incubate at room temperature for 15 minutes in the dark; 5μL of PI staining was added 5 minutes before the machine was put on. After adding 200μL of 1×Binding Buffer, the cells were tested on the machine.

[0095] Immunofluorescence: After treating cells with nanomedicine according to experimental requirements, Caspase3, Caspase9, etc. are used to characterize tumor cell apoptosis; LC3I and LC3II are used to characterize tumor cell autophagy. The specific experimental plan is as above.

[0096] (5) Does API-1@PD1-CCNPs affect the transport of Pin1 substrate oncoproteins and tumor suppressor miRNAs?

[0097] WB and other methods were used to verify whether API-1@PD1-CCNPs had any effect on Pin1 substrate oncoprotein-related pathways such as KRAS, AKT, β-catenin, NF-κB, Cyclin D1, c-JUN and other pathways; immunofluorescence staining IF, qRT-PCR and other methods were used to verify whether API-1@PD1-CCNPs had any effect on the nuclear transport and export of anti-cancer miRNAs. Figure 3 b, c).

[0098] Experimental Example 4

[0099] Effects of API-1@PD1-CCNPs on tumor microenvironment and immune promotion mechanism.

[0100] (1) Combined transcriptome and proteome analysis results to detect changes in key molecules after API-1@PD1-CCNPs treatment

[0101] Tumor tissues from treated and untreated tumor mouse models were separated, and the effects of API-1@PD1-CCNPs on tumor cells at the transcriptional and translational levels were detected by transcriptome sequencing technology RNA-seq and protein non-labeling quantitative technology Label-Free. The sequencing results in the previous step were then verified by immunofluorescence staining, WB, and multiple fluorescent immunohistochemistry staining kits, focusing on detecting changes in Pin1 substrate oncoproteins (such as MYC) and related proteins to further reveal the in vivo anti-cancer molecular mechanism of API-1@PD1-CCNPs. At the same time, markers such as tumor metastasis, apoptosis / necrosis / senescence, and angiogenesis were detected to evaluate the inhibitory effect of API-1@PD1-CCNPs on tumors and clarify the molecular mechanism of API-1@PD1-CCNPs anti-tumor.

[0102] (2) Detection of changes in the tumor microenvironment in various preclinical tumor models after API-1@PD1-CCNPs treatment

[0103] Blood, spleen, lymph nodes and tumor tissues of Hu-PBMC and GEMM tumor models after treatment were isolated, and various immune cells in the tumor microenvironment, such as CD8 + / CD4 + The percentage, number and spatial distribution of infiltration of lymphocytes such as T cells, B cells, NK cells, TAM, APC, etc. Figure 5 c) and changes in cytokines such as IL-12, TNF-α, IFN-γ, TGF-β, PD-L1, etc., to verify whether tumor immune surveillance has been restored and tumor immunity has been mobilized.

[0104] Mouse tumor tissue multicolor flow cytometry: peel off the whole liver, weigh and record the total weight of the liver, take 0.5g of tumor tissue (try to take the same part and the same weight for each mouse) and cut it into 1mm3 fine pieces with scissors. Transfer the chopped liver to the prepared digestion buffer and keep it on ice until the tissue harvest is completed. Add 10mL of digestion solution (preheat the digestion solution at 37℃ after preparation). Digest for 30min at 80rpm on a 37℃ hot shaker, filter the cell suspension with a 70μm filter, pre-wet the filter before filtering and centrifuge at 1500rpm for 3min. Resuspend the cells with 5mL PBS and centrifuge at 1500rpm for 3min. Lyse the red blood cells, lyse on ice for 15min, wash, and resuspend. After counting the cells, divide them into tubes based on the flow staining scheme. Add an appropriate amount of flow antibody to each tube, incubate on ice in the dark for 30min, centrifuge, wash, resuspend, and then detect on the machine.

[0105] Multiple fluorescent immunohistochemistry of mouse tumor tissue: The whole liver was dissected, the total weight of the liver was weighed and recorded, 0.5 g of tumor tissue (the same part and weight were taken from each mouse as much as possible) was placed in a BD tube, fixed with paraformaldehyde, and fluorescent tissue section samples were prepared according to the instructions of the multiple fluorescent immunohistochemistry staining kit. Various immune cells in the tumor microenvironment, such as CD8 + / CD4 + The number and spatial distribution of infiltrating lymphocytes such as T cells, B cells, NK cells, TAM, APC, and changes in cytokines such as IL-12, TNF-α, IFN-γ, TGF-β, PD-L1, etc.

[0106] (3) In vitro simulation of tumor microenvironment to explore the synergistic mechanism between API-1@PD1-CCNPs and immune cells

[0107] A variety of human liver cancer cell lines and immortalized Jurkat T lymphocytes were used to simulate T cell-mediated anti-tumor immune responses in vitro, and flow cytometry, immunofluorescence staining, clone formation, ELISA and other methods were used to verify the T cell activation state and the synergistic tumor killing effect in the presence or absence of API-1@PD1-CCNPs.

[0108] (4) Investigate whether API-1@PD1-CCNPs induce immune memory in mice after treatment

[0109] Induced immune memory experiment: C57BL / 6 mice with spontaneous hepatocellular carcinoma GEMM were first treated with four cycles of API-1@PD1-CCNPs. Orthotopic tumor imaging was performed after the last treatment and the tumor size was recorded. Four mice that had a complete response to the treatment were selected and injected subcutaneously with 5×10 5 The wild-type C57BL / 6 mice were used as controls and injected subcutaneously with the same number of Hepa1-6 cells on day 0 without any pretreatment. The size of the subcutaneous tumor was measured with a caliper every other day from day 7 to day 25, and the tumor volume was calculated according to the following formula: 1 / 2 (length × width × width). Figure 4 and Figure 5 shown.

[0110] Figure 4 The dosing cycle and test time points of the CDX model were designed in a. Figure 4 In b, 2 weeks after tumor formation, CDX tumor mice were injected with DiD fluorescently labeled nanoparticles and naked drugs (DiD instead) through the tail vein. After 72 hours, observation was made using a small animal imaging device, and it was found that the PD1-CCNPs drug delivery system could efficiently deliver active targeted tumor sites. Figure 4In c, the distribution of drugs throughout the body was statistically analyzed, among which PD1-CCNPs had the highest uptake ratio in tumors, showing excellent targeted delivery efficiency. Figure 4 In d, the organs are removed after dissection, and the local results are consistent with the overall results. Figure 4 In e, one week after the CDX model was established, drugs were injected into the tail vein every 3 days, and the tumor growth curve was statistically analyzed. The results showed that API-1@PD1-CCNPs had a better solid tumor intervention effect than API-1 bare drug. Figure 4 In f, Figure 4 In the nude mouse organ tissues (heart, liver, spleen, lung, and kidney) in Figure e, samples were taken for H&E staining and microscopic observation showed that no pathological changes or toxicological reactions were observed in the API-1@PD1-CCNPs group. This result confirms that API-1@PD1-CCNPs has good biocompatibility and has certain clinical application potential.

[0111] Figure 5 In a, the dosing cycle and test time points of the CDX model were designed to verify tumor targeting and calculate drug delivery efficiency. Figure 5 In b, the inhibitory effects of API-1@PD1-CCNPs and API-1 naked drug on spontaneous liver cancer tumors were preliminarily tested one month after administration. It was found that the effect of API-1 naked drug was not significant, while API-1@PD1-CCNPs could effectively inhibit tumors. Figure 5 c, take Figure 5 In b, the tumor tissue was subjected to immunofluorescence experiments, and it was found that the CD8+T cell infiltration in the PD1-CCNPs group was enhanced, and the CD8+T cell infiltration in the API-1-NPs group and the API-1@PD1-CCNPs group was enhanced in turn. Among them, API-1@PD1-CCNPs was the most obvious. This result suggests that the PD1-CCNPs carrier may compete with the tumor cell PD-L1, affect tumor immune escape, and induce T cell infiltration; combined with Figure 3 c Results suggest that after API-1@PD1-CCNPs effectively deliver API-1 to the tumor, it may downregulate PD-L1 in tumor cells, thereby further affecting tumor immune escape.

[0112] (5) Detection of changes in Exosomal PD-L1 after API-1@PD1-CCNPs treatment

[0113] After API-1@PD1-CCNPs treatment, exosomes were extracted from the orthotopic tumor model by ultracentrifugation.

[0114] Collection of peripheral blood exosomes: 1-1.5 mL of mouse peripheral blood was added to a 1.5 mL enzyme-free centrifuge tube and allowed to coagulate at 37°C for 1 hour without anticoagulation. Serum was obtained by centrifugation at 2000×g for 10 min. Serum was then obtained by centrifugation at 3000×g for 10 min; the supernatant was diluted with sterile PBS at a ratio of 1:1 and centrifuged again at 10000×g for 30 min, and then ultracentrifuged at 200000×g for 2 h. The precipitate was resuspended with a large amount of PBS, filtered through a 0.2μm syringe filter, and centrifuged at 200000×g for 1 h, and then the precipitate was collected and resuspended in PBS or culture medium for subsequent functional or biochemical assays. Be careful to avoid too much foaming, as exosomes are present in the resuspension. Transfer PBS to a new EP tube, add 1 mL of TRIzol or cell lysis buffer, protein loading, or DTT to extract nucleic acids or proteins, and wash the ultracentrifuge tube for later use.

[0115] Exosome detection: The expression of PD-L1 on exosomes was detected by SDS-PAGE and WB, and the size and morphology of exosomes were analyzed by transmission electron microscopy; combined with immune labeling, the expression site of PD-L1 in exosomes was analyzed.

[0116] Observation of PD-L1 exosomes inside and outside the cell: Select liver cancer cell lines (SK-Hep1, HepG2, Huh7, etc.) to analyze the differences in the formation of exosomes inside and outside the cells. According to the experimental requirements, a certain concentration of API-1@PD1-CCNPs was used to treat the liver cancer cell lines, and the exosome fluorescent probe or fluorescent fusion protein labeling method was used, combined with immunofluorescence staining of PD-L1, and confocal observation was used to verify whether there were changes in the intracellular growth process of PD-L1-positive exosomes. To collect exosomes in the culture medium, refer to the mouse peripheral blood exosome collection protocol.

[0117] The present invention utilizes the biological characteristics of cancer cell membranes and immune checkpoints to develop a bionic nano drug delivery system named PD1-CCNPs, and applies it to specific examples for exploration. By encapsulating the Pin1 inhibitor API-1 with the non-cytotoxic PD1-CCNPs drug delivery system to synthesize nanoparticles API-1@PD1-CCNPs, its tumor targeting delivery efficiency and tumor intervention effect can be greatly improved, and the MYC and PD-L1 of liver cancer cells can be downregulated to affect tumor immune escape. In addition, as a nano drug delivery carrier, the PD1-CCNPs bionic nano drug delivery system has good biocompatibility and has the potential for application in situ tracing in cells and in vivo visualization therapy. Its outstanding advantages can lay the foundation for future clinical transformation.

[0118] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane, It is characterized in that The steps include: (1) Preparation of API-1-NPs drug-loaded cores; PLGA and API-1 are dissolved in acetone to obtain an organic phase; under stirring conditions, the organic phase is quickly added into water, and after stirring for reaction, an API-1-NPs drug-loaded core is obtained; (2) Construction of API-1@PD1-CCNPs: First, a PD1 overexpression cell line was established, and then the cell membrane was extracted; the extracted cell membrane was wrapped on the surface of API-1-NPs to obtain composite nanoparticles API-1@PD1-CCNPs.

2. The method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane according to claim 1, It is characterized in that In step (1), a certain proportion of carbon-based dendritic macromolecular structure G0-C14 and surfactant TPGS are also added to the organic phase; The added amount of the G0-C14 is 0.025-0.125 mg / mL, and the mass ratio of the surfactant TPGS to PLGA is 1:5-1:

10.

3. The method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane according to claim 1, It is characterized in that In step (1), a fluorescent dye is also added to construct fluorescent nanoparticles; the amount of the fluorescent dye added is 1% of the mass of PLGA.

4. The method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane according to claim 3, It is characterized in that The fluorescent nanoparticles are DiD and / or DiO.

5. The method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane according to claim 1, It is characterized in that In step (2), the specific operation of establishing a PD1 overexpressing cell line is as follows: First, construct a PD1 target gene overexpression vector, then perform transfection or infection, select drugs for screening based on the screening gene of the expression vector, and expand and culture the screened monoclonal cells and identify them.

6. The method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane according to claim 5, It is characterized in that The sequence of the target gene is shown in SEQ ID No. 1; The drug is puromycin or G418.

7. The method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane according to claim 1, It is characterized in that In step (2), the specific operation of extracting the cell membrane is: Start to expand cells in large quantities 5-7 days before extracting cell membranes, digest the cells with PBS, collect them and wash them three times by centrifugation with PBS, resuspend the last collected cells in hypotonic buffer, then sonicate in ice water, collect the supernatant after centrifugation, repeat the above "resuspend - sonicate - centrifugation" operation for the precipitate, mix the two supernatants and centrifuge them, take the supernatant and centrifuge it, add Tris-HCl to the obtained precipitate, blow and centrifuge it, and the precipitate is the purified cell membrane.

8. The method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane according to claim 7, It is characterized in that The specific composition of the hypotonic buffer is: 20mM Tris-HCl, 10mM KCl, 2mM MgCl 2 , 200 mM protease inhibitor concentrate; The PBS is a PBS solution containing 2 mM EDTA, and the Tris-HCl is a Tris-HCl solution containing 1 mM EDTA.

9. The method for constructing a bionic nano drug delivery system based on PD1 engineered cancer cell membrane according to claim 1, It is characterized in that The specific operation of encapsulating the extracted cell membrane on the surface of API-1-NPs is as follows: The extracted cell membrane was added to the syringe of the squeezer, prepared with 1×PBS to a total volume of 1 mL, and squeezed back and forth with the squeezer for more than 20 times, and then the empty membrane bubble structure of the cell membrane was collected from another syringe; the empty membrane bubble and API-1-NPs were mixed according to a proportion and added to the syringe of the squeezer, and squeezed back and forth with the squeezer for more than 20 times, and then the squeezed membrane-wrapped material was collected from another syringe, ultrafiltered and centrifuged, and concentrated and collected.

10. A bionic nano drug delivery system based on PD1 engineered cancer cell membrane constructed according to the method according to any one of claims 1 to 9.

Citation Information

Patent Citations

  • Dosage Suspensions Of Active Pharmaceutical Ingredients

    US20170368042A1

Cited By

  • Functionalized nano-silver cluster probe as well as preparation method and application thereof

    CN122056919A